Lorvotuzumab mertansine
Based on 1 Customer Validation
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.44%
- CAS No.: 1008106-64-6
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Lorvotuzumab mertansine (0.001-100 nM, 8 days) shows targeted cell killing activity against both cell lines, with the IC50 values of 0.2 nM for NCI-H526 and 5 nM for NCI-H69 cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SW2 SCLC xenograft tumor CB.17 SCID mice
-
Dosage:3、17 and 51 mg/kg
-
Administration:i.v., once
-
Result:Showed high anti-tumor activity at a dose of 17 mg/kg with half of the animals being tumor free and complete tumor regression at a dose of 51 mg/kg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1008106-64-6
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Lorvotuzumab mertansine]
-
Synonyms
IMGN-901; BB-1090
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lorvotuzumab mertansine Related Classifications
HY-132262 Related Classifications
Powered by Bioz